CCL22 and prostate neoplasm: Further, in an ex vivo prostate tumor model, celecoxib suppressed intra-tumoral production of the Treg/MDSC-attractant CXCL12 and Treg-attractant CCL22, while increasing the production of the cytotoxic T lymphocyte (CTL) attractant CXCL10.